Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for healthcare industry professionals · Thursday, May 28, 2020 · 518,124,945 Articles · 3+ Million Readers

$35Bn+ Ophthalmic Therapeutics/Drugs Market to 2025: Anti-allergy, Anti-VEGF Agents, Anti-inflammatory, and Anti-glaucoma

/EIN News/ -- Dublin, Aug. 01, 2019 (GLOBE NEWSWIRE) -- The "Ophthalmic Therapeutics/Drug Market Analysis By Class (Anti-allergy, Anti-VEGF Agents, Anti-inflammatory, Anti-glaucoma), By Disease (Dry Eye, Allergies, Glaucoma, Infection, Retinal Disorders, Uveitis), And Segment Forecasts, 2014 - 2025" report has been added to's offering.

The global ophthalmic therapeutics/drugs market is expected to reach USD 35.7 billion by 2025.

Increase in funding by public and private bodies for conducting research on ocular disorders with the presence of strong emerging pipeline drugs are some of the factors responsible for the growth of ophthalmic therapeutics market.

For instance, the recent approval of Zerviate (cetirizine) for the treatment of allergic conjunctivitis in 2017 and Humira (adalimumab) and Xiidra (lifitegrast) in 2016 as ophthalmic solutions for the treatment of uveitis and dry eyes are expected to boost the market growth.

Numerous ongoing public-private partnership agreements in the pharmaceutical industry for the development of novel therapeutics are expected to provide this market with lucrative growth opportunities. In the recent years, a number of highly-effective and safe agents have emerged for the treatment of fungal ophthalmic diseases. Natamycin, amphotericin B, clotrimazole, are some of the most promising therapeutics present in the market.

For instance, in October 2016, Santen Pharmaceuticals, Foundation for Biomedical Research and Innovation (FBRI), and RIKEN announced a research collaboration to develop new treatments for retinal diseases such as age-related macular degeneration and retinitis pigmentosa.

Further Key Findings From the Report Suggest:

  • Antiallergy is the largest segment owing to the increasing incidence of ocular infections, high prescription rate of antiallergy agents, and presence of a wide product portfolio
  • Retinal disorders segment dominated the market in 2016 due to increasing prevalence of age-related macular degenerations and diabetic retinopathy, its subtypes
  • The eye drops segment is anticipated to dominate the market in 2016. It is considered as the most preferred dosage form due to associated benefits such as easy assimilation, target-specific action, and faster recovery
  • Over-the-Counter (OTC) held the largest share in 2016 due to its low cost and increasing preference of OTC over prescription drugs
  • North America dominated the market in 2016 owing to factors such as the increase in demand for ophthalmic solutions for the treatment of glaucoma and dry eyes in this region.
  • Asia-Pacific is anticipated to be the fastest growing region with a lucrative CAGR during the forecast period due to rising disposable income, presence of a large population base, and growing awareness programs by various organizations.
  • Some of the key players in this industry are Allergan; Aerie Pharmaceuticals, Inc.; Pfizer Inc.; Valeant Pharmaceuticals International, Inc.; Bayer AG; Genentech, Inc.; Novartis AG; Regeneron Pharmaceuticals, Inc.; Shire; and Santen Pharmaceutical Co., Ltd

Key Topics Covered

1. Methodology and Scope
1.1 Information Procurement
1.1.1 Purchased database:
1.1.2 Internal database
1.2 Research Methodology
1.3 Geographic scope & assumptions
1.4 Region-wise market calculation
1.4.1 Region-wise market: Base estimates
1.4.2 Global market: CAGR calculation
1.5 Region-based segment share calculation
1.6 List of Secondary Sources

2 Executive Summary
2.1 Market Snapshot

3 Ophthalmic Drug Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.1.1 Market Driver Analysis Increasing incidence and prevalence of eye related disorders Increasing R&D pertaining to the development of novel drugs Presence of strong emerging pipeline drugs Increased funding from both public and private research organizations
3.1.2 Market Restraint Analysis Loss of patent protection for blockbuster drugs
3.2 Penetration & growth prospect mapping
3.3 Ophthalmic Drug - SWOT Analysis, By Factor (political & legal, economic and technological)
3.4 Industry Analysis - Porter's

4 Ophthalmic Drug Market: Drug class Estimates & Trend Analysis
4.1 Ophthalmic drug market: Drug Class Movement Analysis
4.2 Anti-Allergy
4.3 Anti-VEGF (Vascular Endothelial Growth Factor) agents
4.4 Anti-inflammatory
4.5 Anti-glaucoma
4.6 Others

5 Ophthalmic Drug Market: Disease Estimates & Trend Analysis
5.1 Ophthalmic drug market: Disease type movement analysis
5.2 Dry Eye
5.3 Allergies
5.4 Glaucoma
5.5 Inflammation/ Infection
5.6 Retinal Disorders
5.7 Uveitis
5.8 Others

6 Ophthalmic Drug Market: Dosage form Estimates & Trend Analysis
6.1 Ophthalmic drug market: Dosage movement analysis
6.2 Gels
6.3 Eye solutions
6.4 Capsules & Tablets
6.5 Eye drops
6.6 Ointments

7 Ophthalmic Drug Market: Product Estimates & Trend Analysis
7.1 Ophthalmic drug market: Product movement analysis
7.2 Prescription Drugs
7.3 OTC Drugs
7.4 Recent Drug Approval: 2000-2017

8 Ophthalmic Drug Market: Regional Estimates & Trend Analysis, by Test Type
8.1 Ophthalmic drug market share by region, 2016 & 2025
8.2 North America
8.3 Europe
8.4 Asia-Pacific
8.5 Latin America
8.6 MEA

9 Competitive Landscape
9.1 Strategy framework
9.2 Market participation categorization
9.3 Company Profiles

10 Primary Research Analysis
10.1 Factors estimated to impact on market growth
10.2 Market scenario
10.3 Key KoL responses

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                             Laura Wood, Senior Press Manager
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900

Primary Logo

Powered by EIN News
Distribution channels: Culture, Society & Lifestyle, Science

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release